Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Cash Equivalents
â‚ą8.8B
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
55%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash Equivalents
â‚ą7.1B
CAGR 3-Years
-22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash Equivalents
â‚ą9.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash Equivalents
â‚ą90.2B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash Equivalents
â‚ą11.5B
CAGR 3-Years
49%
CAGR 5-Years
14%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Cash Equivalents
â‚ą1.2B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
243B INR
Industry
Pharmaceuticals

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Cash Equivalents?
Cash Equivalents
8.8B INR

Based on the financial report for Jun 30, 2024, Natco Pharma Ltd's Cash Equivalents amounts to 8.8B INR.

What is Natco Pharma Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
55%

Over the last year, the Cash Equivalents growth was 113%. The average annual Cash Equivalents growth rates for Natco Pharma Ltd have been 51% over the past three years , 29% over the past five years , and 55% over the past ten years .

Back to Top